FISCHER vs PAR: Stock Comparison

Fischer Medical Ventures Limited vs Par Drugs And Chemicals Limited

Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings

Fischer Medical Ventures Limited is the larger company by market capitalisation. Fischer Medical Ventures Limited shows a higher dividend yield and faster revenue growth, while Par Drugs And Chemicals Limited shows a lower P/E, a higher ROE and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Fischer Medical Ventures Limited and Par Drugs And Chemicals Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, FISCHER is more favourable on 4 of 13 scored metrics and PAR on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
FISCHER is the larger company
₹2,486 Cr vs ₹116 Cr
P/E Ratio
PAR has a lower P/E
8.55x vs 80.98x
P/B Ratio
PAR has a lower P/B
0x vs 6.48x
EPS
PAR has higher earnings per share
₹10.65 vs ₹0.45
Dividend Yield
FISCHER has a higher dividend yield
0.01% vs 0%
Revenue Growth (TTM YoY)
FISCHER has faster revenue growth
98.7% vs -12.2%
EPS Growth (TTM YoY)
FISCHER has faster EPS growth
0% vs -48.5%
Qtr Sales Growth
FISCHER has stronger quarterly sales growth
98.8% vs -12.2%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricFISCHERPAR
SectorHealthcareHealthcare
IndustryMedical Equipment & SuppliesPharmaceuticals

Price

MetricFISCHERPAR
Live Price₹37.94₹93.79
Day Change-2.79%-2.48%
Volume21.83 L12,063
52-Week High₹1,194.4₹114
52-Week Low₹31.05₹78.05
Distance from 52W High-96.82%-17.73%

Valuation

MetricFISCHERPAR
Market Cap₹2,486 Cr₹116 Cr
P/E Ratio80.98x8.55x
P/B Ratio6.48x0x
EPS₹0.45₹10.65
Book Value₹5.96₹90.52
Dividend Yield0.01%0%

Growth

MetricFISCHERPAR
Revenue Growth (TTM YoY)98.7%-12.2%
EPS Growth (TTM YoY)0%-48.5%
Qtr Sales Growth98.8%-12.2%
Qtr Profit Growth-642%-48.5%

Profitability & Leverage

MetricFISCHERPAR
ROE8.59%12.4%
ROCE11.4%16.5%
Net Margin6.79%12.65%
Operating Margin14%16.5%
Debt to Equity0.28x0x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricFISCHERPAR
Promoter Holding11.46% 0.82 pp73.41%
FII Holding4.97% 0.12 pp0%
DII Holding1.38% 0.02 pp0.09% 0.09 pp
Public Holding31.5% 0.49 pp26.51% 0.08 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Fischer Medical Ventures Limited and Par Drugs And Chemicals Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.